Clinical Data Relay drug shows early promise against rare blood vessel diseases pharminent May 19, 2026
Clinical Data BioMarin suffers another blow to rare disease portfolio in Phase 3 flop pharminent May 19, 2026
Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis pharminent May 19, 2026
Regulatory VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain pharminent May 19, 2026
M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates pharminent May 19, 2026
Other 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator pharminent May 18, 2026
Clinical Data Merck ADC, licensed from China, hits mark in first big global trial pharminent May 18, 2026
M&A / Deals Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B pharminent May 18, 2026
Policy / Pricing Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019 pharminent May 18, 2026
Regulatory AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs pharminent May 18, 2026
Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies pharminent May 18, 2026
Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications pharminent May 18, 2026
Clinical Data Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate pharminent May 15, 2026
Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term pharminent May 15, 2026
Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results pharminent May 14, 2026
Pipeline Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism pharminent May 14, 2026
Regulatory With new data, Regenxbio to seek FDA approval of Duchenne gene therapy pharminent May 14, 2026
M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs pharminent May 14, 2026
